Yili Group welcomed outstanding employees from around the world to its second Global Elite Summit, held in Hohhot, Inner Mongolia, from July 7–10. The four-day gathering brought together 52 high-achieving team members from Indonesia, Thailand, New Zealand, the Netherlands, Germany, and Australia. Created to strengthen collaboration across regions, the event combined cultural experiences, visits to company facilities, and interactive team-building programs to reinforce connections among Yili's international workforce.

Chairman and President Pan Gang joined the event to greet participants and take part in the traditional "dragon eye-dotting" ceremony, a symbolic ritual representing new beginnings and renewed energy. During the ceremony, he presented commemorative gifts to attendees and reaffirmed the importance of Yili's global talent in supporting the company's long-term vision.

Addressing the participants, Pan Gang emphasized that international expansion continues to be a central focus of Yili's development strategy. He noted that as the company broadens its global operations, it will continue creating greater opportunities for overseas employees to advance their careers and achieve professional growth.

One of the summit's standout experiences was a guided visit to the Yili Modern Intelligent Health Valley. Employees explored every stage of the dairy production process, gaining insight into how advanced digital technologies, intelligent manufacturing systems, and extensive research and development work together to maintain Yili's high standards for quality and food safety. The visit underscored the company's shared commitment to delivering trusted products to consumers worldwide.

An employee from Indonesia described the experience as highly motivating, saying that witnessing Yili's dedication to quality firsthand inspired them to apply the same standards in their own market and continue providing premium products to local customers.

Beyond the business-focused activities, the summit also highlighted cultural diversity and international friendship. Participants experienced traditional Chinese customs, toured Hohhot, and showcased the music, dance, and traditions of their own countries, creating opportunities for meaningful cross-cultural exchange.

Among the event's most memorable activities was a collaborative dragon dance project. Teams worked together to design, build, and perform with a traditional dragon, demonstrating how cooperation, creativity, and mutual support can overcome language differences and strengthen teamwork.

Reflecting on the experience, one Chinese employee observed that although participants spoke different languages and came from diverse backgrounds, the spirit of mutual respect and care united everyone throughout the event.

The Global Elite Summit represents an important part of Yili's long-term talent development strategy. By fostering an inclusive, multicultural workplace where employees from different regions can thrive, the company continues to strengthen its global workforce while encouraging professional growth and collaboration.

As Yili looks to the future, it plans to build on these shared experiences to inspire innovation, deepen international cooperation, and contribute to the continued advancement of the global health industry.

Americans for Safe and Effective Medicines (ASEM) has been established as a national advocacy organization focused on safeguarding patients from the risks associated with illegal large-scale drug compounding, counterfeit medications, and deceptive marketing practices. The organization also aims to hold companies and individuals accountable for practices that may compromise patient safety. Its launch coincides with the release of its first national survey, which found that while 84% of consumers prefer GLP-1 medications that have received approval from the U.S. Food and Drug Administration (FDA), only 17% are aware that compounded GLP-1 products do not undergo FDA approval.

Compounded GLP-1 products continue to be widely promoted through telehealth providers, medical spas, online vendors, and other distribution channels. These marketing practices often fail to clearly distinguish FDA-approved medicines from compounded alternatives, leading many patients to mistakenly assume that all such products meet the same regulatory standards for safety, effectiveness, and quality.

Fred Mills, Chief Policy Officer at ASEM, stated that many patients are making treatment decisions without receiving complete information about the products they use. He noted that ASEM was created to address a marketplace where consumer misunderstanding has become commercially advantageous. According to Mills, pharmaceutical compounding was originally intended to address the unique needs of individual patients rather than serve as a large-scale commercial enterprise.

Survey Highlights: Consumer Expectations vs. Awareness
The organization's survey identified a substantial gap between consumer expectations and their understanding of compounded GLP-1 medications:

Report Highlights Risks Associated with Mass Compounding
In addition to the survey, ASEM released a report titled The Shortage is Over. The Risks Are Not: How Illegal Mass Compounding Is Undermining Patient Safety—And What Must Happen Next. The report argues that temporary compounding practices permitted during the GLP-1 drug shortage have expanded into a largely unregulated commercial market for compounded GLP-1 products. According to the report, these products are distributed outside many of the regulatory safeguards that apply to FDA-approved medicines.

Drawing on FDA inspection records, product recalls, warning letters, and state regulatory enforcement actions, the report concludes that patient safety is being compromised by several factors, including: